Avidity Biosciences Delpacibart Etedesiran Receives FDA Breakthrough Therapy Designation for Myotonic Dystrophy Type 1
Avidity Biosciences, a company specializing in RNA therapeutics, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to delpacibart etedesiran (AOC 1001).
This designation is for Avidity’s leading program aimed at treating myotonic dystrophy type 1 (DM1), a serious and often fatal neuromuscular disorder with no approved treatments.
This advanced RNA therapeutic uses the company’s innovative Antibody Oligonucleotide Conjugate (AOC) platform to target and reduce the levels of the DMPK mRNA that causes DM1.
By combining a proprietary monoclonal antibody with siRNA, Delpacibart etedesiran effectively reduces DMPK mRNA in muscle cells, which has shown promising results in early studies, including the MARINA-OLE™ trial.
This open-label, multi-center study will monitor the therapy over approximately 24 months of treatment, followed by a nine-month safety follow-up.
The therapy has earned several key FDA designations—Breakthrough Therapy, Orphan Drug, and Fast Track—and has also received Orphan designation from the European Medicines Agency (EMA).
As it moves into a global Phase 3 study called HARBOR™, which will evaluate outcomes such as video hand opening time and improvements in muscle strength and daily activities, Delpacibart etedesiran stands out as a significant advancement in addressing the critical unmet needs of DM1 patients.
